|
|
| | Derazantinib Basic information |
| Product Name: | Derazantinib | | Synonyms: | (6R)-6-(2-fluorophenyl)-5,6-dihydro-N-[3-[2-[(2-methoxyethyl)amino]ethyl]phenyl]-Benzo[h]quinazolin-2-amine;ARQ-087;CPD1093;Derazantinib;Derazantinib (ARQ-087);(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine;ARQ-087;ARQ087;ARQ 087;CPD1093;CS-2677 | | CAS: | 1234356-69-4 | | MF: | C29H29FN4O | | MW: | 468.57 | | EINECS: | | | Product Categories: | | | Mol File: | 1234356-69-4.mol |  |
| | Derazantinib Chemical Properties |
| Boiling point | 615.1±65.0 °C(Predicted) | | density | 1.218±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:47.67(Max Conc. mg/mL);101.73(Max Conc. mM)
DMF:30.0(Max Conc. mg/mL);64.02(Max Conc. mM)
DMF:PBS (pH 7.2) (1:3):0.25(Max Conc. mg/mL);0.53(Max Conc. mM) | | form | A crystalline solid | | pka | 9.04±0.19(Predicted) |
| | Derazantinib Usage And Synthesis |
| Uses | Derazantinib is an intermediate in the preparation of imidazopyridinyl compounds for treating proliferative disorders like cancer, Proteus syndrome and others. |
| | Derazantinib Preparation Products And Raw materials |
|